PTCy is named as an intervention in 2 current clinical trials in our China and Belgium registers. 2 are recruiting patients now. All registered phases are Phase 2. The sponsor with the most trials is Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1). The most-studied condition is Graft-Versus-Host Disease(GVHD).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
NCT03852407 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission
|
Phase 2 | Recruiting | University of Liege | Belgium |
|
Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors
NCT07570745 · ClinicalTrials.gov ↗ · Graft-Versus-Host Disease(GVHD), Bone Marrow Transplantation
|
Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| University of Liege | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Belgium | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Belgium registers name PTCy as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in China and 1 with sites in Belgium. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) and University of Liege (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how PTCy works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PTCy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PTCy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.